News & Insights

Recent News

BlackArch Partners Advises Avanti Polar Lipids on its Sale to Croda International

CHARLOTTE, NC  (July 14, 2020) – BlackArch Partners (“BlackArch”) is pleased to announce that it advised Avanti Polar Lipids, Inc. (“Avanti” or the “Company”) on its pending sale to Croda International Plc (“Croda”).

Avanti (www.avantilipids.com), headquartered in Alabaster, AL, is a leader in the development and manufacturing of high-purity lipids and associated pharmaceutical services that are utilized as drug delivery solutions for complex therapeutic drugs and next generation mRNA vaccines. The Company operates from its campus in Alabama with its skilled workforce of approximately 150 employees, including over 100 scientists. Throughout Avanti's history, the Company has been an innovator in lipid-based products and applications for the life sciences markets and currently serves thousands of leading biopharmaceutical companies and researchers around the world.

The Company has two primary revenue streams in research products and pharmaceutical services. Since the Company's founding it has been a leader in developing lipids for life science research and currently offers over 2,000 lipid and adjuvant products. The Company also offers pharmaceutical services where it leverages its lipid based expertise to develop and supply drug delivery solutions for complex therapeutics. Avanti provides a comprehensive range of services from formulation and analytical services through cGMP manufacturing of synthetic lipids and adjuvants for clinical and commercial applications.

Avanti's know-how and technologies are highly complementary to Croda's capabilities in drug delivery systems, vaccine adjuvants and immunotherapy. Avanti will be able to combine its leading position in pharmaceutical lipid-based applications with Croda's access to global markets, greater manufacturing capacity and a broader set of capabilities to expand the range of products and services for the combined customer base.

Dr. Walter Shaw, CEO of Avanti, commented: “We selected BlackArch given their unique combination of a deep understanding of our markets that span research products and pharmaceutical services, extensive knowledge of the global buyer universe and a dedicated middle-market M&A focus. They did an outstanding job of preparing us for a transaction, finding the right strategic partner and then navigating us through a global pandemic to an exceptional outcome.”

BlackArch was retained by Avanti to serve as its exclusive financial advisor.  The transaction continues BlackArch’s significant momentum in the pharmaceutical services and healthcare sectors and is representative of the firm’s focus on providing dedicated M&A advisory services to market-leading businesses.

 

 

About BlackArch Partners

BlackArch Partners is a leading middle-market investment bank offering a full spectrum of advisory services to financial sponsors, private companies and diversified corporations. BlackArch addresses the needs of companies with specialized services that include M&A advisory, strategic advisory and private capital solutions. Headquartered in Charlotte, NC, BlackArch features a total of 12 industry-focused practices that cover all sectors of interest to middle-market investors; BlackArch professionals have closed more than 350 transactions in 16 countries on four continents. Please visit our website, www.blackarchpartners.com, for more details.

Securities offered through BlackArch Securities LLC. Member FINRA and SIPC.  Testimonials may not be representative of the experience of all clients.  Testimonials are not a guarantee of future performance or success.

About Avanti Polar Lipids

More at: www.avantilipids.com 

Founded in 1967 by Dr. Walter and Rowena Shaw, Avanti specializes in the development and production of high-purity polar lipids that are used in next-generation drug delivery technology and mRNA vaccines. It has two primary revenue streams:

  • Research Products: sales of a wide range of high-purity lipid products for pharmaceutical research and development
  • Pharmaceutical Services: comprehensive liposomal drug delivery development and production solutions. In addition to its formulation and analytical capabilities, Avanti provides a production capability, to the highest quality and regulatory standards (known as Good Manufacturing Practice or GMP), to support customers' drug development, clinical trials and commercial supply of novel drug delivery systems.

With its extensive portfolio, Avanti serves biotechnology and large pharmaceutical companies around the world. 

About Croda International

More at: www.croda.com

Established in 1925, Croda is the name behind sustainable, high performance ingredients and technologies in some of the world's most successful brands: creating, making and selling specialty chemicals that are relied on by industries and consumers everywhere.

Croda is a FTSE100 company with over 4,500 passionate and innovative employees, working across manufacturing sites and offices around the world with a shared Purpose to use Smart Science to Improve Lives™. As part of this Purpose, and with around two thirds of its organic raw materials already from bio-based sources, Croda has committed to be the most sustainable supplier of innovative ingredients, becoming Climate, Land and People Positive by 2030.